IOVA
Iovance Biotherapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$8.48Close
$3.5BMarket cap
$1.81 – $14.8652-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, over 25% off the high
- Far from its high 43% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
43%
1wk
down 39.8%
price change
1mo
down 42.8%
price change
12-month return
up 335%
market up 11% ·
its own up 313%
F-score
4 / 9
Weak
Altman Z
4.74
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.0×
price / book
Earnings yield
down 12.1%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
up 61%
year on year
EPS growth
—
latest quarter
Sales growth
up 66%
latest quarter · +21 pts
ROE
down 56%
return on equity
Free cash margin
down 128%
-$336.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitability improving
- profits backed by cash
- reduced long-term debt
- assets working harder
Trade setup
ATR%
14.6%
$1.23 a day · 2×ATR $6.01
RS
99 / 99
vs the universe
Trend
6 / 8
under the 50-day, over 25% off the high
Relative volume
1.9×
vs 50-day average
Up/down volume
1.09
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- Within 25% of the 52-week high: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 35.0% over the year, from 305m to 412m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 43.2% to 34.3%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Oct 29, 2026-35% in one session3.7× volumeon an SEC filing-11% since
Financials
- Gross 34%
- Net -148%
- Free cash -128%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $1.2M | $164.1M | $263.5M |
| Gross margin | — | — | — | 13% | 43% | 34% |
| Operating income | -$261.9M | -$342.7M | -$398.9M | -$460.6M | -$395.3M | -$403.4M |
| Net income | -$259.6M | -$342.3M | -$395.9M | -$444.0M | -$372.2M | -$391.0M |
| Net margin | — | — | — | -37342% | -227% | -148% |
| Earnings per share | -$1,876.93 | -$2,231.33 | -$2,485.89 | -$1,888.31 | -$1,283.99 | -$1,094.18 |
| Free cash flow | -$251.9M | -$265.5M | -$313.2M | -$384.1M | -$364.0M | -$336.2M |
| Free cash margin | — | — | — | -32305% | -222% | -128% |
| Cash | $67.3M | $78.2M | $231.7M | $114.9M | $115.7M | $163.1M |
| Long-term debt | — | $1.0M | $1.0M | $1.0M | $1.0M | — |
| Shareholders' equity | $656.5M | $621.7M | $499.6M | $584.6M | $710.4M | $698.6M |
| Shares outstanding | 147.87m | 157m | 187.81m | 256.14m | 305.25m | 411.94m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Other events ↗ |
| Oct 5, 2026 | Other events ↗ |
| Sep 29, 2026 | Other events ↗ |
| Aug 6, 2026 | Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jul 2, 2026 | Other events ↗ |
| Jun 10, 2026 | Shareholder vote · Other events ↗ |
| May 7, 2026 | Results ↗ |
| Mar 20, 2026 | Director or officer change ↗ |
| Feb 24, 2026 | Results · Other events ↗ |
| Jan 9, 2026 | Other events ↗ |
| Nov 6, 2025 | Results ↗ |